JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shannon, H. E.
Right arrow Articles by Swedberg, M. D.B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shannon, H. E.
Right arrow Articles by Swedberg, M. D.B.

Vol. 290, Issue 2, 901-907, August 1999

Muscarinic Receptor Agonists, Like Dopamine Receptor Antagonist Antipsychotics, Inhibit Conditioned Avoidance Response in Rats

Harlan E. Shannon, John C. Hart, Frank P. Bymaster, David O. Calligaro, Neil W. DeLapp, Charles H. Mitch, John S. Ward, Anders Fink-Jensen, Per Sauerberg, Lone Jeppesen, Malcolm J. Sheardown and Michael D.B. Swedberg

Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (H.E.S, J.C.H., F.P.B., D.O.C., N.W.D, C.H.M., J.S.W.); and Novo Nordisk A/S, Health Care Discovery, Måløv, Denmark (A.F.J., P.S., L.J., M.J.S., M.D.B.S)

The purpose of our studies was to determine the effects of muscarinic receptor agonists on conditioned avoidance responding in the rat. Rats were trained to avoid or escape an electric shock delivered to the feet in a discrete trial procedure. The muscarinic receptor agonists pilocarpine and [2-ethyl-8-methyl-2,8-diazaspiro(4.5)decane-1,3-dione] hydrochloride (RS86) and the cholinesterase inhibitor physostigmine all decreased the percentage of avoidance responses at doses that produced less than approximately 30% response failures. Similar results were obtained with the antipsychotic drugs haloperidol, trifluoperazine, chlorpromazine, and clozapine. However, the benzodiazepine anxiolytic diazepam did not decrease avoidance responding up to doses that produced ataxia. On the other hand, oxotremorine and arecoline decreased avoidance responding only by producing response failures, whereas aceclidine produced intermediate changes. The muscarinic receptor antagonists scopolamine, trihexyphenidyl, and benztropine were without effect when administered alone but antagonized the decreases in avoidance responding produced by pilocarpine and RS86. Scopolamine had little effect on the decreases in avoidance responding produced by haloperidol. The newer muscarinic receptor partial agonists or agonist/antagonists [R-(Z)-(+)-alpha -(methoxyimino)-1-azabicyclo[2.2.2]octane-3-acetonitrile] hydrochloride, talsaclidine, milameline, and xanomeline also produced dose-related decreases in avoidance responding. Our results demonstrate that muscarinic receptor agonists can decrease avoidance responding in a manner similar to dopamine-receptor antipsychotic drugs, suggesting that muscarinic receptor agonists may provide an alternative approach to the treatment of psychosis.


0022-3565/99/2902-0901$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Am. J. PsychiatryHome page
A. Shekhar, W. Z. Potter, J. Lightfoot, J. Lienemann, S. Dube, C. Mallinckrodt, F. P. Bymaster, D. L. McKinzie, and C. C. Felder
Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia
Am J Psychiatry, August 1, 2008; 165(8): 1033 - 1039.
[Abstract] [Full Text] [PDF]


Home page
Schizophr BullHome page
A. Breier
Developing Drugs for Cognitive Impairment in Schizophrenia
Schizophr Bull, October 1, 2005; 31(4): 816 - 822.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
C. K. Jones, E. L. Eberle, D. B. Shaw, D. L. McKinzie, and H. E. Shannon
Pharmacologic Interactions between the Muscarinic Cholinergic and Dopaminergic Systems in the Modulation of Prepulse Inhibition in Rats
J. Pharmacol. Exp. Ther., March 1, 2005; 312(3): 1055 - 1063.
[Abstract] [Full Text] [PDF]


Home page
Schizophr BullHome page
M. Sarter, C. L Nelson, and J. P Bruno
Cortical Cholinergic Transmission and Cortical Information Processing in Schizophrenia
Schizophr Bull, January 1, 2005; 31(1): 117 - 138.
[Abstract] [Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
T. J. Raedler, M. B. Knable, D. W. Jones, R. A. Urbina, J. G. Gorey, K. S. Lee, M. F. Egan, R. Coppola, and D. R. Weinberger
In Vivo Determination of Muscarinic Acetylcholine Receptor Availability in Schizophrenia
Am J Psychiatry, January 1, 2003; 160(1): 118 - 127.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
K. J. Stanhope, N. R. Mirza, M. J. Bickerdike, J. L. Bright, N. R. Harrington, M. B. Hesselink, G. A. Kennett, S. Lightowler, M. J. Sheardown, R. Syed, et al.
The Muscarinic Receptor Agonist Xanomeline Has an Antipsychotic-Like Profile in the Rat
J. Pharmacol. Exp. Ther., November 1, 2001; 299(2): 782 - 792.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.